MYOFORMIN
Live / Allowed — Notice of allowance issued (as of 11 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 19 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99092562
- Mark type
- Stylized text
- Filed
- 19 Mar 2025
- Published for opposition
- 16 Sept 2025
- Attorney of record
- Erica M Hines
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications; or conditions or complications associated with any of the foregoing; Nutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Nutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength
Owner
- Emmyon, Inc., Rochester, MN, US
- Emmyon, Inc., Rochester, MN, US
Prosecution history
- 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Oct 2025 — POST PUBLICATION AMENDMENT - ENTERED
- 23 Oct 2025 — ASSIGNED TO PETITION STAFF
- 16 Sept 2025 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Sept 2025 — PUBLISHED FOR OPPOSITION
- 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Aug 2025 — ASSIGNED TO EXAMINER
- 19 Mar 2025 — APPLICATION FILING RECEIPT MAILED
- 19 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 19 Mar 2025 — NEW APPLICATION ENTERED